- Details
- Zachary Klaassen and Christopher Wallis discuss the NCCN guidelines for castration-resistant prostate cancer (CRPC) updated in February of 2021. Biographies: Christopher J.D. Wallis, MD, Ph.D., Assistant Professor in the Division of Urology at the University of Toronto Zachary Klaassen, MD, MSc, Urologic Oncologist, Assistant Professor Surgery/Urology at the Medical College of Georgia at Augusta U...
|
- Details
- UroToday is introducing an in-depth look at the NCCN Guidelines on Prostate Cancer. In this video presentation, Zachary Klaassen and Christopher Wallis focus on Androgen Deprivation Therapy (ADT), which is broken down into six subsections including ADT for clinically localized N0M0 disease, ADT for regional disease, palliative ADT, ADT for castration-naive disease, intermittent versus continuous A...
|
- Details
- At the 2021 ASCO GU Cancers Symposium, Dr Robert Motzer and colleagues presented the results of the CLEAR study examining first-line lenvatinib and everolimus or lenvatinib and pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma and concurrent with the presentation, CLEAR was published in the New England Journal of Medicine. In this UroToday Journal Club, Christopher Wall...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss a publication entitled Efficacy of Enzalutamide Plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: a Post Hoc Analyses of the ARCHES trial . The present study relies upon secondary analysis of the ARCHES trial, a multinational randomized controlled trial th...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss the TALAPRO-1 study, an internationally conducted clinical trial that assesses the effectiveness of talazoparib in the treatment of metastatic castration-resistant prostate cancer (mCRPC) with DNA repair alterations. The study is an open-label, phase II trial and includes patients with progressive mCRPC who have had at...
|
- Details
- In this UroToday GU Oncology Journal Club, Christopher Wallis and Zachary Klaassen highlight a Journal of Clinical Oncology publication on a phase two open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma, progressing after platinum-based chemotherapy and checkpoint inhibitors. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With M...
|
- Details
- In this UroToday Journal Club Christopher Wallis and Zachary Klaassenthey discuss, “An Adaptive Biomarker-Directed Platform Study of Durvalumab in Combination with Targeted Therapies in Advanced Urothelial Cancer”. This Journal Club kicks off with an overview of advanced urothelial carcinoma, which then transitions into a discussion on the background and controls of this study. About halfway throu...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss a retrospective analysis of randomized trials that suggest that Black men with metastatic castration-resistant prostate cancer (mCRPC) have longer survival than White men, a prospective study of abiraterone acetate plus prednisone to explore outcomes by race. The goal of this study was to first demonstrate the feasibili...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss the first-in-human phase 1 study of belzutifan (MK-6482), a potent, selective small molecule inhibitor of Hypoxia-inducible factor-2α (HIF-2α). HIF-2α is a transcription factor that frequently accumulates in clear cell renal cell carcinoma (ccRCC), resulting in the constitutive activation of genes involved in carcinogen...
|
- Details
- In this UroToday journal club, Christopher Wallis and Zachary Klaassen discuss a pilot study on Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer (mHSPC) patients. The discussion begins with a look into the evolution of mHSPC treatment over the past five years, with an acknowledgment of the CHAARTED, STAMPEDE, and GETUG trials. Dr. Wallis also discusses the prevalenc...
|
